泰恩康：关于全资子公司利多卡因丙胺卡因气雾剂收到药品注册受理通知书的公告

Core Viewpoint - The announcement indicates that TianKang's subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a notice of acceptance for the registration application of Lidocaine and Prilocaine aerosol from the National Medical Products Administration (NMPA) of China [1] Group 1 - The application for the drug registration has been accepted by the NMPA based on the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China [1]